Sandoz launches two new bone disease biosimilars in Europe
Esme Needham | December 3, 2025 | News story | Sales and Marketing | Oncology, Osteoporosis, Sandoz
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 mg) is approved for the treatment of cancer-related bone disease, while Jubbonti (denosumab 60 mg) is approved for osteoporosis treatment.
The medicines have been approved by the European Commission for all indications of their reference medicines, Amgen’s Xgeva (denosumab 120mg) and Prolia (denosumab 60mg).
Cancer remains a leading cause of premature death for people aged 30-69 in the majority of European countries. Most types of cancer can spread to the bone, causing pain and fractures; the most frequently metastasising cancers include breast, lung and prostate. Additionally, around 32 million people over 50 in Europe are estimated to live with osteoporosis. Few high-risk patients currently receive treatment for the condition, and the number of yearly fractures in Europe is set to increase by almost 25% by 2034. These figures highlight the need for innovative and affordable bone disease treatments.
Wyost and Jubbonti contain the monoclonal antibody denosumab, which works to inhibit osteoclast formation, function and survival and decrease bone resorption. The two medicines will be launched across Europe, with additional rollouts to follow later in 2026.
Christophe Delenta, president Europe at Sandoz, said: “We know that primary and secondary bone loss, and cancer-related bone events, place a significant burden on millions of patients and their families, as well as on European healthcare systems. That’s why the launch of these denosumab biosimilars is such an important milestone, expanding access to these potentially life-changing medicines and reinforcing our commitment to delivering sustainable treatment options for patients.”
Related Content
Sandoz signs renewable energy deal to supply 90% of European operations
Sandoz has entered into a ten-year virtual Power Purchase Agreement with Elawan Energy for the …
FDA approves Sandoz’s denosumab biosimilars
Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) …
Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America
Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung …
